MedTrace Logo

Anti-OX40 Antibody in Head and Neck Cancer Patients

NCT02274155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-02-07

No results posted yet for this study

Summary

The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.

Conditions

Interventions

DRUG

Anti-OX40 antibody administration

Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study

PROCEDURE

Surgical Resection

Surgical Resection of Tumor

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Richard B. Bell, MD · Providence Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-12
Primary Completion
2017-09-17
Completion
2023-12-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02274155 on ClinicalTrials.gov